Alembic Pharmaceuticals Recalls One Lot of Telmisartan Tablets

March 24, 2021 – Alembic Pharmaceuticals has voluntarily recalled a single lot of Telmisartan Tablets, USP, 20mg, packaged in 30-count bottles. The recall is due to a customer complaint that a bottle contained 30 tablets of Telmisartan Tablets, USP, 40mg.

Telmisartan is indicated to treat hypertension (high blood pressure). Patients who mistakenly take a doubled dose of telmisartan for a prolonged period could experience low blood pressure, declining kidney function, or potentially life-threatening elevated potassium levels. Alembic has received no reports of adverse events related to the affected product as of the date of the recall.

The manufacturer advises patients who may be in possession of the recalled telmisartan to speak to their pharmacist or healthcare provider about a replacement before returning to the place of purchase or discontinuing use. Questions regarding the recall can be directed to Alembic at 1-908-552-5839 or david.cobb@alembicusa.com. Patients should contact their healthcare provider if they have experienced any issues that may be related to using the affected product. Adverse events can also be reported to the U.S. FDA’s MedWatch program.

A full copy of the recall notice is available on the FDA’s website.